Somatrogon-Ghla

Introduction Overview

Generic Name

somatrogon-ghla

Brand Name

Ngenla

Dosage Form

pre-filled injectable pen for subcutaneous use (24 mg/1.2 mL, 60 mg/1.2 mL)

Drug Class

Growth hormones

Pharmacokinetics

Absorption:
Ngenla (somatrogon-ghla) is administered via subcutaneous injection, from where it is slowly absorbed into the systemic circulation. Its unique molecular structure, a fusion of human growth hormone (hGH) and a portion of human chorionic gonadotropin (hCG), prolongs its absorption and persistence in circulation, enabling once-weekly dosing. Peak plasma concentrations are typically achieved several hours post-administration. The absorption kinetics are influenced by the injection site, local blood flow, and individual patient factors, such as the presence of subcutaneous fat and tissue perfusion. Clinical studies have demonstrated consistent and predictable absorption profiles, supporting its use in pediatric growth hormone deficiency (GHD).

Distribution:
Once absorbed, somatrogon distributes widely into the extracellular fluid compartments and tissues where growth hormone receptors are located, including liver, muscle, and bone. The protein's large size due to the hCG portion reduces renal clearance and extends the plasma half-life to approximately 70-80 hours, compared to natural growth hormone's shorter half-life of approximately 3.8 hours. Volume of distribution has been characterized as low to moderate, reflecting predominant vascular and interstitial distribution rather than intracellular localization. Somatrogon binds to growth hormone receptors in target tissues to exert its biological effects, and it circulates bound to plasma proteins without significant accumulation.

Metabolism:
Somatrogon undergoes proteolytic degradation primarily in the liver and peripheral tissues. The fusion design slows metabolism compared to native growth hormone, contributing to the sustained pharmacodynamic effects. Enzymatic cleavage by proteases breaks down the protein into smaller peptides and amino acids, which are further metabolized via normal proteolytic pathways. Unlike small molecules, somatrogon is not metabolized by cytochrome P450 enzymes, but it may influence the metabolism of other drugs through indirect mechanisms. Metabolic clearance rates are relatively stable but may vary with age, concomitant disease, and hormonal status.

Elimination:
Elimination of somatrogon occurs mainly through proteolytic degradation followed by renal excretion of amino acids and small peptides. Intact protein is not appreciably excreted in urine. Its prolonged half-life is a consequence of decreased renal clearance and slower metabolism facilitated by the hCG fusion segment. The dosage and frequency have been optimized based on elimination kinetics to maintain effective plasma levels with weekly administration. No significant accumulation is noted with chronic use. Clearance may be impacted by renal or hepatic impairment, although data are limited in these populations.

Clinical Implications:
Ngenla's pharmacokinetics allows for a more convenient once-weekly dosing regimen compared to daily injections required for several other growth hormone therapies. This can improve patient adherence and quality of life, particularly in pediatric populations. The extended half-life and steady plasma concentrations reduce the incidence of peak-related side effects. However, dosage individualization is necessary to balance efficacy and safety, with monitoring of growth response and IGF-1 levels essential for optimal therapeutic outcomes.

Dosage Forms

Available Dosage Forms:
Ngenla is available exclusively as a pre-filled disposable injectable pen for subcutaneous use, manufactured as single-patient-use pens in two strengths:
- 24 mg/1.2 mL (20 mg/mL) pen delivering doses in 0.2 mg increments
- 60 mg/1.2 mL (50 mg/mL) pen delivering doses in 0.5 mg increments
The pens are designed for once-weekly administration and are intended for use by a single patient only. They contain slightly more than labeled doses to account for priming and delivery variability, but the maximum deliverable doses per injection are capped according to pen strength.

Dosages for Adults and Adolescents:
Ngenla is specifically approved and used in children aged 3 years and older with growth hormone deficiency to stimulate growth and development. The recommended dose is 0.66 mg/kg based on actual body weight administered once weekly. Dosage should be individualized depending on the patient's clinical response and growth velocity. Dosing adjustments are made by the prescribing healthcare provider. For patients switching from daily growth hormone injections, therapy with Ngenla can commence on the day following the last daily dose.

Injections above the maximum single-injection dose require multiple injections at different sites administered sequentially, ensuring adequate full dosing without compromising absorption or increasing injection site reactions.

Specific Patient Populations:
Ngenla has not been extensively studied in adults with growth hormone deficiency or other indications; it is specifically indicated for pediatric use. Use in patients with closed epiphyses is contraindicated. Dose adjustments may be necessary in patients with concomitant health conditions affecting glucose metabolism or hormone balance, such as diabetes or hypothyroidism. Patients with a history of malignancy, intracranial hypertension, or Prader-Willi syndrome require specialized monitoring.

Injection sites may include abdomen, thighs, buttocks, or upper arms with weekly rotation to minimize injection site adverse effects such as lipodystrophy or tissue atrophy. Caregiver or patient training on correct dosing and injection technique is critical to ensure efficacy and safety.

Patients should avoid sharing injection pens or needles to mitigate infection risks. Specific handling and storage instructions must be adhered to, including refrigeration prior to use and disposal protocols for used pens.

Mechanism Of Action

Ngenla (somatrogon-ghla) functions as a long-acting analog of human growth hormone by directly interacting with growth hormone receptors (GHR) located on the surfaces of target cells predominantly in liver, muscle, bone, and adipose tissue. Upon binding to GHR, it triggers receptor dimerization and activation of intracellular signaling cascades, chiefly the JAK2-STAT5 pathway, leading to transcriptional regulation of genes involved in growth and metabolic processes.

A critical downstream mediator is Insulin-Like Growth Factor 1 (IGF-1), whose synthesis is primarily induced in hepatocytes. Elevated circulating IGF-1 promotes systemic effects including stimulation of longitudinal bone growth by activating growth plates in long bones, enhancing amino acid uptake and protein synthesis in muscle, and modulating carbohydrate and lipid metabolism. These actions collectively contribute to improved growth velocity and normalization of growth deficits in children with growth hormone deficiency.

The unique molecular design of Ngenla incorporates a fusion of native human growth hormone and a segment derived from human chorionic gonadotropin. This structural modification significantly prolongs its half-life, enabling sustained receptor engagement and biological activity, permitting once-weekly dosing instead of daily injections required by traditional growth hormone preparations. The extended action is achieved by decreased renal clearance and resistance to proteolytic degradation, maintaining therapeutic plasma levels over extended periods.

Clinical studies demonstrate that somatrogon elicits similar or improved pharmacodynamic responses compared to conventional daily somatropin therapies, ensuring effective stimulation of IGF-1 production and growth promotion with improved patient adherence. By mimicking endogenous growth hormone activity over a prolonged timeframe, Ngenla ensures maintenance of physiologic growth hormone signaling with a favorable safety profile. Comparative analyses show that its mechanism is consistent with other growth hormone analogs but optimized for duration of effect and dosing convenience.

Pharmacological Actions

Acts as a human growth hormone receptor agonist, stimulating normal growth functions.
Induces hepatic production of Insulin-Like Growth Factor 1 (IGF-1) to mediate systemic growth effects.
Promotes longitudinal bone growth by activating growth plates in pediatric patients.
Enhances protein synthesis and amino acid transport in muscle and other tissues.
Modulates carbohydrate metabolism by influencing insulin sensitivity and glucose utilization.
Stimulates lipolysis and affects lipid metabolism, contributing to body composition changes.
Exerts anabolic effects that increase muscle mass and reduce fat mass.
Possesses prolonged plasma half-life allowing for sustained receptor activation and once-weekly dosing.
Bypasses rapid clearance and degradation mechanisms through fusion protein design.
Lacks intrinsic immunogenicity in most patients, minimizing neutralizing antibody formation.
Regulates metabolic homeostasis influencing energy expenditure.
Contributes to overall pediatric growth hormone deficiency management through normalization of growth velocity.
Minimal impact on cytochrome P450 enzymes, but may indirectly influence metabolism of other drugs.
Activates JAK2-STAT5 signaling pathway essential for transcriptional growth-related gene expression.
Exhibits pharmacologic effects consistent with endogenous growth hormone but with improved pharmacokinetics.

Therapeutic Or Clinical Uses

Treatment of pediatric growth hormone deficiency (GHD) in children aged 3 years and older.
Indicated to promote height increase in children with insufficient endogenous growth hormone production.
Used as a replacement therapy in children who exhibit reduced growth velocity due to GHD.
Option for patients requiring long-acting growth hormone replacement facilitating once-weekly injections.
Alternative to daily somatropin formulations, improving treatment adherence and patient convenience.
Management of children with growth failure resulting from pituitary or hypothalamic dysfunction.
Potential therapy in select pediatric patients transitioning from daily growth hormone therapies.
Adjunct therapy monitored with IGF-1 levels to optimize dosing and growth response.
Avoided in patients with closed epiphyses or active malignancies.
May be used in clinical scenarios where reduced injection burden is clinically advantageous.
Employed following comprehensive assessment confirming growth hormone deficiency.
Prescribed under specialist supervision with ongoing monitoring for efficacy and safety.
Part of integrated treatment including nutritional support and management of underlying conditions.
Used in patients without presence of contraindications such as critical illness or severe obesity in Prader-Willi syndrome.
Facilitates catch-up growth and normalizes height velocity trajectories in affected children.

Side Or Adverse Effects

Injection site reactions including pain, swelling, redness, itching, and occasional bleeding.
Common cold and upper respiratory tract infections.
Headache, ranging from mild to moderate intensity.
Fever episodes reported in some pediatric patients.
Anemia characterized by low red blood cell counts.
Cough and respiratory symptoms.
Gastrointestinal complaints such as nausea, vomiting, and abdominal pain.
Rash and other mild dermatological reactions.
Throat pain or discomfort.
Decrease in thyroid hormone levels leading to potential hypothyroidism.
Fluid retention manifesting as swelling in hands, feet, or other dependent areas.
Joint and muscle pain possibly related to fluid accumulation or growth stimulation.
Nerve-related symptoms such as burning, tingling, or numbness in extremities.
Potential development of intracranial hypertension evidenced by headache, vision changes, or nausea.
Hypoglycemia or hyperglycemia with disturbances in glucose metabolism requiring monitoring.

Precautions

Do not use in patients with critical illness related to recent heart or stomach surgery, trauma, or severe respiratory issues.
Careful monitoring required in children with history of cancer or tumors, particularly those previously treated with cranial radiation.
Monitor blood glucose regularly in patients with or at risk for diabetes.
Assess thyroid and cortisol hormone levels before and during treatment to detect insufficiencies.
Rotate injection sites weekly to prevent localized tissue atrophy or lipodystrophy.
Avoid use in patients with closed epiphyses as no benefit is expected.
Use cautiously in children with Prader-Willi syndrome who are severely obese or have respiratory issues.
Regular clinical evaluation for signs of intracranial hypertension.
Observe patients for development or worsening of scoliosis during therapy.
Dose adjustments may be necessary when co-administered with glucocorticoids or oral estrogens.
Monitor for signs of fluid retention including edema or rapid weight gain.
Ensure proper training in injection technique to prevent dosing errors.
Be vigilant for allergic reactions and discontinue therapy immediately if suspected.
Regular clinical and laboratory monitoring is essential to optimize dosing and detect adverse events.
Avoid sharing pens or needles to minimize infection risk.

Warnings

Increased risk of mortality in patients with critical illness secondary to major surgery, trauma, or respiratory failure.
Potential for serious hypersensitivity and allergic reactions including anaphylaxis.
Risk of tumor growth stimulation in patients with active or residual malignancies.
Possibility of intracranial hypertension requiring prompt recognition and management.
Elevated blood sugar and development or worsening of diabetes mellitus may occur.
Fluid retention can lead to peripheral edema and neuropathy symptoms.
Cortisol insufficiency may lead to adrenal crisis if untreated.
Risk of slipped capital femoral epiphysis or worsening scoliosis in growing children.
Severe abdominal pain may indicate pancreatitis, necessitating immediate evaluation.
Localized lipoatrophy or fat redistribution can occur at injection sites if rotation is inadequate.
Not recommended for use in children with Prader-Willi syndrome who are severely obese or have breathing difficulties.
Avoid use after epiphyseal closure as it may be ineffective and increase risk of adverse effects.
High vigilance required in monitoring for signs of malignancy recurrence in previously treated patients.
Sudden death has been reported in high-risk pediatric populations, underscoring the need for thorough assessment prior to initiation.
Use caution in patients with diabetic retinopathy or other diabetic complications.

Contraindication

Known hypersensitivity to somatrogon-ghla or any component of the formulation.
Critical illness due to complications from heart surgery, abdominal surgery, trauma, or respiratory failure.
Closed epiphyses indicating completed bone growth.
Active malignancy or presence of tumors.
Presence of certain diabetic eye problems such as diabetic retinopathy.
Children with Prader-Willi syndrome who are severely obese or have significant breathing difficulties including sleep apnea.
Concurrent use in patients with intracranial hypertension without appropriate monitoring.
Use in patients with untreated hypothyroidism or adrenal insufficiency until these conditions are corrected.
Patients with severe allergic reactions to other growth hormone products.
Contraindicated in patients with acute critical illness or multiple organ system failure.
Use is not approved in neonates or children under 3 years of age.
Patients with uncontrolled diabetes or poorly managed metabolic disorders.
Any patient with history of life-threatening allergy to human proteins or excipients.
Contraindicated in patients who have an active proliferative or severe systemic illness.
Patients with known or suspected cancer should not start therapy without oncologic clearance.

Drug Interactions

Glucocorticoids can antagonize growth hormone action and may require dose adjustments.
Estrogens administered orally may reduce growth hormone efficacy, potentially necessitating increased dosing.
Somatrogon may influence the clearance of drugs metabolized by cytochrome P450 enzymes indirectly, affecting their plasma levels.
Insulin and other antihyperglycemic agents may require dose modification due to alterations in glucose metabolism induced by growth hormone therapy.
Concomitant use with somatrogon and glucocorticoids may attenuate growth-promoting effects.
Medications affecting renal or hepatic function could alter somatrogon pharmacokinetics though clinical significance is limited.
Somatrogon treatment may necessitate careful monitoring when used with drugs that affect fluid balance due to risk of edema.
No significant interactions with common over-the-counter medications have been reported, but vigilance is warranted.
Potential interaction with immunosuppressive agents has not been firmly established; caution advised.
Warfarin and other anticoagulants are not directly affected but baseline coagulation parameters should be monitored.
Patients taking CYP450 substrates with narrow therapeutic indices should be monitored for altered drug levels.
Concomitant use with other hormonal therapies requires monitoring for additive or antagonistic effects.
Interaction profiles are based on limited evidence; clinicians should monitor clinical response and adverse effects rigorously.
Vaccinations should be timed appropriately as immune response may be modulated by growth hormone therapy.
The list is not exhaustive; comprehensive medication review is essential before initiating and during therapy.

Preparations Of The Drug

Ngenla is supplied as a sterile, preservative-containing, liquid injectable solution in single-patient-use disposable pre-filled pens.
Available in two concentrations: 24 mg/1.2 mL and 60 mg/1.2 mL.
Each pen delivers multiple doses, with dosing increments of 0.2 mg for the 24 mg pen and 0.5 mg for the 60 mg pen.
Pens are designed for once-weekly subcutaneous injections and require proper storage refrigerating between 2°C and 8°C prior to first use.
After initial use, the pen should be stored refrigerated and used within 28 days before disposal.
The injection solution contains somatrogon-ghla as active ingredient with excipients including citric acid monohydrate, histidine, metacresol (preservative), poloxamer 188, sodium chloride, sodium citrate, and water for injection.
Prefilled pens are engineered for ease of use with dose dial knobs enabling accurate dose selection.
Needles are not included and must be attached separately; use a new sterile needle for each administration.
Pens must not be shared between patients to prevent cross-infection.
The device includes safety features to prevent unintentional dosing or dosage errors.
Disposal instructions recommend pens be discarded in approved sharps containers.
No generic or biosimilar versions of Ngenla currently available; distributed exclusively by Pfizer Ireland Pharmaceuticals.
Manufactured under strict quality control in compliance with regulatory standards.
Instructions for use emphasize avoiding shaking of the pen to maintain protein stability.
Stability and storage conditions are detailed in accompanying prescribing information to ensure drug integrity.